Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-τ

Human Antibodies

Volumn 7, Issue 1, 1996, Pages 21-26

  Qi, Yumin ^a   Moyana, Terence ^a   Chen, Yue ^b   Xiang, Jim ^b  

^a Saskatoon Cancer Center   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Anti tumor immunity; CD8+T lymphocyte; Fusion protein; Macrophage

Indexed keywords

CD8 ANTIGEN; HYBRID PROTEIN; INTERFERON; TUMOR VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLUORESCENCE ACTIVATED CELL SORTER; GENETIC ENGINEERING; HISTOLOGY; INOCULATION; MACROPHAGE; METASTASIS; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR RECURRENCE; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOGLOBULIN FAB FRAGMENTS; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0029962473     PISSN: 10932607     EISSN: 1875869X     Source Type: Journal    
DOI: 10.3233/HAB-1996-7103     Document Type: Article

References (29)

1. De Maeyer E, De Maeyer-Guignard J. Interferons and Other Regulatory Cytokines. New York: John Wiley and Sons, 1988
2. Ros F, Cochet M, Fellous M. Interferon and major histocompatibility complex genes: A model to analyze eukaryotic gene regulation. In: (Gresser I, ed.) Interferon-x, London: Academic Press, 1986
3. Schwartz R, Momburg F, Moldenhauer G, Dorken B, Schirrmacher V. Induction of HLA class II antigen expression on human carcinoma cell lines by IFN-x. Int J Cancer 1985; 35: 245
4. Fady C, Gardner A, Gera J, Lichtenstein A. Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: Selective effects on HER2/neu expressing cells. Cancer Res 1992; 52: 764
5. Tanaka K, Isselbacher K, Khoury G, Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 1985; 228: 26
6. Greiner J, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher P, Schlom J. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 1987; 235: 895
7. Kantor J, Tran R, Greiner J, Pestka S, Fisher P, Shively J, Schlom J. Modulation of carcinoembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant human i-interferon. Cancer Res 1989; 49: 2651
8. Adams D, Hamilyon T. Molecular transduction mechanisms by which IFN-gamma and other signals regulate macrophage development. Immunol Rev 1987; 97: 5
9. Weigent D, Stanton J, Johnson H. Recombinant gamma interferon. Biochem Biophys Res Commun 1983; 111: 525
10. Sone S, Utsugi T, Ogura T. Differential effects of recombinant interferon alpha, beta and gamma on induction of human lymphokine-activated killer activity. J Natl Cancer Inst 1988; 80: 425
11. Kurzrock R. Interferon gamma. In: Cytokine Therapy, Galvani, D W, Cawley, J C eds. Cambridge: Cambridge University, 1992
12. Cantell K, Fiers W, Hirvonen S, Pyhala L. Circulating interferon in rabbit after simultaneous intramuscular administration of human alpha and gamma interferons. J Interferon Res, 1984; 4: 291
13. Quesada J, Evans L, Saks S, Gutterman J. Recombinant interferon alpha and gamma in combinations as treatment for metastatic renal cell carcinoma. J Biol Resp Modif 1988; 7: 234
14. Kurzrock R, Rosenblum M, Sherwin S. Pharmacokinetics, single dose tolerance and biological activity of recombinant gamma interferon in cancer patients. Cancer Res, 1985; 45: 2866
15. FitzGerald D, Willingham M, Cardarelli C, Hamada H, Tsuruo T, Gottesman M, Pastan I. A monoclonal antibody-pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. PNAS, 1987; 84: 4288
16. Harven E, Fradet Y, Connolly J, Hana W, He S, Wang Y, Choi BMcGroarty R, Bootsma G, Tilup A, Christensen H. Antibody drug carrier for immunotherapy of superficial bladder cancer. Ultra-structural Studies. Cancer Res 1992; 52: 3131
17. Schmidberger H, Buchsbaum D, Blazar B, Everson P, Vallera D. Radiotherapy in mice with Yetrium-90-labeled anti-Lyl monoclonal antibody: therapy of the T cell lymphoma EL4. Cancer Res 1991; 51: 1883
18. Hoogenboom H, Volckaert G, Raus J. Construction and expression of antibody-tumor necrosis factor fusion protein. Mol Immunol 1991; 28: 1027
19. Xiang J, Qi Y, Chen Y, Moyana T. Targeting gamma interferon to tumor cells by a genetically engineered bifunctional fusion protein RM4/IFN-T. Hum Antibod Hybridomas 1996 7: 2
20. Qi Y, Chen Y, Xiang J. Mouse myeloma cell line secreting fusion protein RM4/IFN-T elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo. J Interferon Cytokine Res Revised, 1996.
21. Xiang J, Moyana T, Kaira J, Hamilton T, Qi Y. Construction and characterization of a high-affinity chimeric anti-colorectal carcinoma antibody ccM4. Mol Biother 1992; 4: 174
22. Norusis M. Statistical Package of Social Science for Windows. Base System User’s Guide. Release 6.0, SPSS Inc., Chicago 1993
23. John Coligan, Ada Kruisbeek, David Margulies, Ethan Shevach, Warren Strober. Current Protocols in Immunology, New York: John Wiley and Sons, 1991
24. Kelley R, Keist R. Abilities of activated macrophages to manifest tumoricidal activity and to generate reactive nitrogen intermediates: a comparative study in vitro and ex vivo. Biochem Biophys Res Commun 1989; 164: 968
25. Giovarelli M, Cofano F, Vecchi A, Forni M, Landolf S, Forni G. Interferon-activated tumor inhibition in vivo. Int J Cancer 1986; 37: 141
26. Colombo M, Modesti A, Parmiani G, Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 1992; 52: 4853
27. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated T-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990; 50: 7820
28. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E, Taniyama T, Sakata T. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma CI300 cells results in reduced tumorigenicity by augmented antitumor immunity. PNAS 1989; 86: 9456
29. Restifo N, Spiess P, Karp S, Mule J, Rosenberg S. A non-immunogenic sarcoma transduced with the cDNA for interferon elicits CD8 T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 1992; 175: 1423